Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

被引：8

作者：

Bagnasco, Diego ^{[1
,2
]}

Nicola, Stefania ^{[3
]}

Testino, Elisa ^{[1
,2
]}

Brussino, Luisa ^{[3
]}

Pini, Laura ^{[4
]}

Caminati, Marco ^{[5
]}

Piccardo, Federica ^{[2
]}

Canevari, Rikki Frank ^{[6
]}

Melissari, Laura ^{[1
,2
]}

Ioppi, Alessandro ^{[6
]}

Guastini, Luca ^{[6
]}

Lombardi, Carlo ^{[7
]}

Milanese, Manlio ^{[8
]}

Losa, Francesca ^{[9
]}

Robbiano, Michela ^{[1
,2
]}

De Ferrari, Laura ^{[1
,2
]}

Riccio, Anna Maria ^{[1
,2
]}

Guida, Giuseppe ^{[10
]}

Bonavia, Marco ^{[11
]}

Fini, Donatella ^{[12
]}

Balbi, Francesco ^{[13
]}

Caruso, Cristiano ^{[14
]}

Paggiaro, Pierluigi ^{[15
]}

Blasi, Francesco ^{[16
,17
,18
]}

Heffler, Enrico ^{[19
,20
]}

Paoletti, Giovanni ^{[19
,20
]}

Canonica, Giorgio Walter ^{[19
,20
]}

Senna, Gianenrico ^{[5
]}

Passalacqua, Giovanni ^{[1
,2
]}

机构：

[1] Univ Genoa, IRCCS Policlin San Martino, Allergy & Resp Dis, I-16132 Genoa, Italy

[2] Univ Genoa, Dept Internal Med DIMI, I-16132 Genoa, Italy

[3] AO Ordine Mauriziano Torino, SCDU Immunol & Allergol, Cso Re Umberto 109, I-10128 Turin, Italy

[4] Spedali Civili Brescia, Resp Med Unit, Piazzale Spedali Civili 1, I-25123 Brescia, Italy

[5] Univ Verona, Dept Med, I-37134 Verona, Italy

[6] Univ Genoa, ENT Dept, IRCCS Policlin San Martino, I-16132 Genoa, Italy

[7] Fdn Poliambulanza, Dept Unit Allergol Immunol & Pulm Dis, I-25124 Brescia, Italy

[8] ASL2, S Corona Hosp, Dept Resp Dis, I-17027 Pietra Ligure, Italy

[9] ASST Mantova, UO Allergol & Clin Immunol, I-46100 Mantua, Italy

[10] Univ Torino, Dept Clin & Biol Sci, Orbassano 10043, Italy

[11] ASL3, Hosp Ge Arenzano, Dept Rehabil Pulmonol, I-16149 Genoa, Italy

[12] Hosp Sarzana SP, Dept Pneumol, I-19125 La Spezia, Italy

[13] Hosp Imperia, Dept Pneumol, I-18100 Imperia, Italy

[14] Univ Cattolica Sacro Cuore, Dept Med & Surg Sci, Fdn Universitary Policlin A Gemelli IRCCS, I-20123 Rome, Italy

[15] Univ Pisa, Dept Surg Med & Mol Pathol & Crit Care, I-56126 Pisa, Italy

[16] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy

[17] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Resp Unit, I-20122 Milan, Italy

[18] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Adult Cyst Fibrosis Ctr, Internal Med Dept, I-20122 Milan, Italy

[19] IRCCS Human Clin & Res Hosp, Unit Personalized Med Asthma & Allergy, I-20089 Rozzano, Italy

[20] Humanitas Univ, Dept Biomed Sci, I-20072 Pieve Emanuele, Italy

来源：

BIOMEDICINES | 2023年 / 11卷 / 09期

关键词：

severe asthma; eosinophils; mepolizumab; CRSwNP; IL-5; real life; registry; SEVERE EOSINOPHILIC ASTHMA; MULTICENTER;

D O I：

10.3390/biomedicines11092424

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The efficacy mepolizumab in severe asthmatic patients is proven in the literature. Primarily to study the effect of mepolizumab on exacerbations, steroid dependence, and the continuation of efficacy in the long term. Secondarily to evaluate the effect of the drug on nasal polyps. Analyzing data from SANI (Severe Asthma Network Italy) clinics, we observed severe asthmatic patients treated with mepolizumab 100 mg/4 weeks, for a period of 3 years. 157 patients were observed. Exacerbations were reduced from the first year (-84.6%) and progressively to 90 and 95% in the second and third ones. Steroid-dependent patients decreased from 54% to 21% and subsequently to 11% in the second year and 6% in the third year. Patients with concomitant nasal polyps, assessed by SNOT-22, showed a 49% reduction in value from baseline to the third year. The study demonstrated the long-term efficacy of mepolizumab in a real-life setting.

引用

页数：10

共 50 条

[1] Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
Khatri, Sumita
Moore, Wendy
Gibson, Peter G.
Leigh, Richard
Bourdin, Arnaud
Maspero, Jorge
Barros, Manuel
Buhl, Roland
Howarth, Peter
Albers, Frank C.
Bradford, Eric S.
Gilson, Martyn
Price, Robert G.
Yancey, Steven W.
Ortega, Hector
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (05) : 1742 - +
[2] Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study
Crimi, Claudia
Nolasco, Santi
Noto, Alberto
Maglio, Angelantonio
Quaranta, Vitaliano Nicola
Di Bona, Danilo
Scioscia, Giulia
Papia, Francesco
Caiaffa, Maria Filomena
Calabrese, Cecilia
D'Amato, Maria
Pelaia, Corrado
Campisi, Raffaele
Vitale, Carolina
Ciampo, Luigi
Dragonieri, Silvano
Minenna, Elena
Massaro, Federica
Gallotti, Lorena
Macchia, Luigi
Triggiani, Massimo
Scichilone, Nicola
Valenti, Giuseppe
Pelaia, Girolamo
Barbaro, Maria Pia Foschino
Carpagnano, Giovanna Elisiana
Vatrella, Alessandro
Crimi, Nunzio
Southern Italy Network Severe Asthma Therapy
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (12) : 3315 - 3327
[3] Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis
Basagana, Maria
Martinez-Rivera, Carlos
Padro, Clara
Garcia-Olive, Ignasi
Martinez-Colls, Mimar
Navarro, Juan
Pardo, Laura
Cruz, Paula
Cardona Peitx, Gloria
Carabias, Lidia
Roger, Albert
Abad, Jorge
Rosell, Antoni
ANNALS OF MEDICINE, 2024, 56 (01)
[4] Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study
Khurana, Sandhya
Brusselle, Guy G.
Bel, Elisabeth H.
FitzGerald, J. Mark
Masoli, Matthew
Korn, Stephanie
Kato, Motokazu
Albers, Frank C.
Bradford, Eric S.
Gilson, Martyn J.
Price, Robert G.
Humbert, Marc
CLINICAL THERAPEUTICS, 2019, 41 (10) : 2041 - 2056
[5] Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study
Pavord, Ian
Chan, Robert
Brown, Nicola
Howarth, Peter
Gilson, Martyn
Price, Robert G.
Maspero, Jorge
ANNALS OF MEDICINE, 2024, 56 (01)
[6] Long-Term Efficacy and Safety Among Patients With Severe Eosinophilic Asthma Treated With Mepolizumab and Its Effect on Small Airways
Strauss, Ronald
Leflein, Hannah
Kolesar, Anna
Hammel, Jeffrey
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (12) : 3670 - 3679.e2
[7] A Single Center Experience of Super-Responders Among Severe Asthma Patients Receiving Treatment with Mepolizumab
Atayik, Emel
Aytekin, Gokhan
TURKISH THORACIC JOURNAL, 2022, 23 (05): : 348 - 354
[8] Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy
Fyles, Fred
Nuttall, Amy
Joplin, Hannah
Burhan, Hassan
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (09) : 2715 - 2723
[9] Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
Lombardi, Carlo
Menzella, Francesco
Berti, Alvise
DRUGS IN CONTEXT, 2024, 13
[10] Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype
Gupta, Atul
Ikeda, Masanori
Geng, Bob
Azmi, Jay
Price, Robert G.
Bradford, Eric S.
Yancey, Steven W.
Steinfeld, Jonathan
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 144 (05) : 1336 - +

← 1 2 3 4 5 →